key: cord-0053315-0fb49vcx authors: Millar, Jonathan E.; Suen, Jacky Y.; McAuley, Daniel F. title: Reply to Zhang and Hei: Mesenchymal Stem Cell–derived Exosomes: Are They Another Therapeutic Method for Extracorporeal Membrane Oxygenation–supported Acute Respiratory Distress Syndrome? date: 2020-12-01 journal: Am J Respir Crit Care Med DOI: 10.1164/rccm.202007-2995le sha: 5931e7c555fdf1b2ed636c5ca13b1fb5c29d8ca2 doc_id: 53315 cord_uid: 0fb49vcx nan Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells Dev 2020;29:747-754. 5. Abraham A, Krasnodembskaya A. Mesenchymal stem cell-derived extracellular vesicles for the treatment of acute respiratory distress syndrome. Stem Cells Transl Med 2020;9:28-38. 6 . Varkouhi AK, Jerkic M, Ormesher L, Gagnon S, Goyal S, Rabani R, et al. Extracellular vesicles from interferon-g-primed human umbilical cord mesenchymal stromal cells reduce Escherichia coli-induced acute lung injury in rats. Anesthesiology 2019;130:778-790. Copyright © 2020 by the American Thoracic Society From the Authors: We thank Zhang and Hei for their insightful comments on our study of mesenchymal stromal cells (MSCs) in a sheep model of extracorporeal membrane oxygenation and acute respiratory distress syndrome (ARDS) (1) . Their principal thesis is that the adverse interaction that we observed, between MSCs and the membrane oxygenator, may be overcome by substituting MSCs with MSCderived exosomes. This proposal has merit. The MSC secretome has been of interest as a therapeutic for some time, particularly MSCderived extracellular vesicles (2), MSC-derived exosomes (3), and MSC-conditioned media (4). These each offer several theoretical advantages over conventional MSC therapy. First, contents of the secretome do not express major histocompatibility complex antigens, removing concerns about immunogenicity. Second, components of the secretome are, in general, easier to store and less susceptible to the adverse effects of storage on efficacy. Third, components of the MSC secretome are much smaller than the cells from which they are derived and thus less likely to be subject to "trapping" in the pulmonary circulation (5) . Recently, an early phase trial of an MSCderived exosome treatment for severe coronavirus disease (COVID-19) has been reported with no apparent safety issues (6) . However, there are some unresolved issues that should be borne in mind. Paracrine actions are the principle means by which MSCs exert benefit in ARDS, although several alternative mechanisms have been described, such as mitochondrial transfer from MSCs to damaged alveolar epithelial cells (7) . The inability of secretome-based therapies to reproduce these actions may limit their efficacy (8, 9) . The translation of MSC secretome-based therapies is also limited by challenges in scaling manufacturing for clinical purposes, an issue that is overcome by the use of induced pluripotent cell-derived MSCs, like those used in our study (1) . With specific regard to our study, the observation that pulmonary emboli were more frequent in the induced pluripotent cell-derived MSC group may not be uniquely associated with the use of a cell-based therapy. A variety of preclinical studies have described the procoagulant activity of MSC-derived extracellular vesicles (10, 11) . Despite these caveats, Zhang and Hei's point is well made and highlights the work that is still required to successfully advance cell therapy for ARDS, especially in the context of extracorporeal organ support. We hope that our study illustrates the usefulness of clinically relevant, high-fidelity animal models in advancing these efforts. n To the Editor: We have read with great interest the research letter authored by Jonkman and colleagues (1), and we agreed with the notion that suboptimal filtering of the electrical activity of the diaphragm (EAdi) signal together with a low threshold (.1 mV) , could lead to incorrect interpretation of patient-ventilator interactions when detected by automated software. In our reported validation investigation of Better Care software (2), the algorithm performance was made against five different experts' opinions using 1,024 tracings of airway flow and airway pressure waveform from 16 different patients, with a reported sensitivity of 91.5% and specificity of 91.7%. Subsequently, as an additional confirmation, we used EAdi tracings with a threshold .1 mV in eight mechanically ventilated patients, obtaining a sensitivity of 65.2% and a specificity of 99.3%. This value was selected on an a priori basis, considering a midpoint between 0.1 mV and 2 mV and was intended to avoid inspiratory assistance during expiration in those cases when the EAdi peak is ,1.5 mV and the cycling-off is at a 40% threshold from EAdi peak, instead of the usual 70% (3). The drop in sensitivity of Better Care algorithm when EAdi was used could be due to, as the authors speculate, a mistaken overestimation of ineffective efforts by EAdi, leading to an increase in false-negative results in the Better Care algorithm. We have seriously considered this possibility in those tracings validated against EAdi, and we have reanalyzed tracings from that previously published cohort, searching for the best cutoff value of EAdi signal with the best performance. The new findings show that the best cutoff value of EAdi is 2.3 mV, with a sensitivity of 89.2%, a specificity of 96%, a positive predictive value of 72.5%, and a negative predictive value of 98.7%. Combined mesenchymal stromal cell therapy and extracorporeal membrane oxygenation in acute respiratory distress syndrome: a randomized controlled trial in sheep Administration of mesenchymal stem cells during ECMO results in a rapid decline in oxygenator performance Acute respiratory distress syndrome Combined mesenchymal stromal cell therapy and extracorporeal membrane oxygenation in acute respiratory distress syndrome: a randomized controlled trial in sheep Mesenchymal stem cell-derived extracellular vesicles for the treatment of acute respiratory distress syndrome Stem cell derived exosomes-based therapy for acute lung injury and acute respiratory distress syndrome: a novel therapeutic strategy Mesenchymal stromal cell conditioned media for lung disease: a systematic review and meta-analysis of preclinical studies Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19 Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury Mesenchymal stromal cells are more effective than the MSC secretome in diminishing injury and enhancing recovery following ventilator-induced lung injury Mesenchymal stromal cells are more effective than their extracellular vesicles at reducing lung injury regardless of acute respiratory distress syndrome etiology Effect of MSCs and MSCderived extracellular vesicles on human blood coagulation Adipose-derived mesenchymal stem cells release microvesicles with procoagulant activity